0001193125-22-140479.txt : 20220504 0001193125-22-140479.hdr.sgml : 20220504 20220504161705 ACCESSION NUMBER: 0001193125-22-140479 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220504 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc CENTRAL INDEX KEY: 0001232524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981032470 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33500 FILM NUMBER: 22891727 BUSINESS ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 353-1-634-7800 MAIL ADDRESS: STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE STREET 2: WATERLOO ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030513 8-K 1 d197099d8k.htm 8-K 8-K
Jazz Pharmaceuticals plc false 0001232524 0001232524 2022-05-04 2022-05-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 4, 2022

 

 

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

Ireland   001-33500   98-1032470

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

 

Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland D04 E5W7
(Address of principal executive offices, including zip code)

011-353-1-634-7800

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, nominal value $0.0001 per share   JAZZ   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01.

Other Events.

On May 4, 2022, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that it has entered into an exclusive licensing agreement with Sumitomo Pharma Co., Ltd. for the Company to acquire rights in the United States, Europe and other territories for DSP-0187, a potent, highly selective oral orexin-2 receptor agonist. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number		   

Description

99.1    Press release date May 4, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:  

/s/ Renée Galá

Name:   Renée Galá
Title:   Executive Vice President and Chief Financial Officer

Date: May 4, 2022

EX-99.1 2 d197099dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and

Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

Jazz licenses development and commercialization rights in U.S., Europe and other territories; Sumitomo

Pharma retains rights in Japan, China and other Asia/Pacific territories

Sumitomo Pharma to receive $50 million upfront payment

Jazz continues to expand neuroscience pipeline and strengthen leadership in sleep medicine

DUBLIN and OSAKA, Japan – May 4, 2022 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) today announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma’s investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441.

Sumitomo Pharma initiated a Phase 1 trial in Japan of DSP-0187 in November 2021 to evaluate safety, tolerability and pharmacokinetics in healthy volunteers. Jazz expects to rapidly advance development of DSP-0187 based on these clinical findings.

“Orexin agonism is an exciting area of sleep disorder research and an approach that may be complementary to oxybate therapy. We believe that DSP-0187 has the potential to advance the treatment of narcolepsy and other sleep disorders based on its profile,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. “As a leader in sleep medicine, we are committed to delivering innovative therapies to people who are living with debilitating sleep disorders. We look forward to leveraging our expertise in sleep disorders to rapidly advance this promising therapy into clinical trials in the U.S. and Europe. This agreement exemplifies both our ability to identify promising compounds that have the potential to improve patient care and our corporate objective of making strategic, value-creating investments in our pipeline.”

“DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist, which is a novel small molecule compound originally created by Sumitomo Pharma by utilizing our advanced expertise in drug discovery for central nervous system disorders. We are pleased to partner with Jazz on DSP-0187 given their strong track record of development success and commercial execution in sleep disorders and long-term commitment to advancing therapies to improve the lives of people with sleep disorders,” said Toru Kimura, Representative Director, Executive Vice President of Sumitomo Pharma. “Jazz’s accomplishments in sleep medicine make the company an ideal partner for us as DSP-0187 enters its next phase of development.”

Orexins are neuropeptides that play an important role in the regulation of sleep and wakefulness. DSP-0187 is a potent, highly selective orexin-2 receptor agonist designed to activate orexin signaling. DSP-0187 is initially planned to be evaluated in patients with narcolepsy, a debilitating sleep disorder which can manifest clinically with cataplexy, excessive daytime sleepiness (EDS), disrupted nighttime sleep (DNS), sleep paralysis and other symptoms. There is also potential for DSP-0187 to treat other sleep disorders.

Transaction Terms

Under the terms of the agreement, Jazz will receive an exclusive license to develop and commercialize DSP-0187 throughout the world except for Japan, China and certain other Asia/Pacific countries and regions, where Sumitomo Pharma will retain all development and commercialization rights. Sumitomo Pharma will receive an upfront payment of $50 million, and is eligible to receive development, regulatory and commercial milestone payments of up to $1.09 billion. Pending approval, Sumitomo Pharma is eligible to receive a tiered, low double-digit royalty on Jazz’s net sales of DSP-0187.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (NASDAQ: Jazz) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

About Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and other Asian countries with more than 7,000 employees worldwide. Sumitomo Pharma defines its corporate mission as “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.” One of its research focus areas is psychiatry and neurology and Sumitomo pharma is promoting competitive drug discovery research based on its proprietary drug discovery platforms established by continuously incorporating cutting-edge technologies. Additional information about Sumitomo Pharma is available through its corporate website at https://www.sumitomo-pharma.com. 

Jazz Pharmaceuticals plc Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to DSP-0187’s potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders; the potential future development, manufacturing, regulatory and commercialization activities; potential future payments by Jazz Pharmaceuticals to Sumitomo Pharma for development, regulatory and commercial milestones as well as tiered royalties based on future net sales; and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals’ current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: Jazz Pharmaceuticals’ ability

to achieve the expected benefits (commercial or otherwise) from the license agreement; pharmaceutical product development and clinical success thereof; the regulatory approval process; effectively commercializing any product candidates; and other risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals plc’s Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2021 and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Sumitomo Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management’s assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.

Jazz Media Contact:

Kristin Bhavnani

Head of Global Corporate Communications

Jazz Pharmaceuticals plc

CorporateAffairsMediaInfo@jazzpharma.com

Ireland +353 1 637 2141

U.S. +1 215 867 4948

Jazz Investor Contact:

Andrea N. Flynn, Ph.D.

Vice President, Head, Investor Relations

Jazz Pharmaceuticals plc

Investorinfo@jazzpharma.com

Ireland +353 1 634 3211

U.S. +1 650 496 2717

Sumitomo Pharma Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)

EX-101.SCH 3 jazz-20220504.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 jazz-20220504_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 jazz-20220504_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g197099dsp1a.jpg GRAPHIC begin 644 g197099dsp1a.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @," M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( #L"/0,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M "@ H * /FKX_?M6_"7]G6SCC\8:I/J7BF[M_M&E^"M 6*\\07<3;Q'=7*22 MQP:1I[.A47-Y+$&PPA65E*CTLORK%YA+]Q#EIQTE4EI!>5]V_)?.Q]3PWP?G M/$U1_4:*I86F[5,35O"C!Z7BFDY3FD_A@G;3F<4[GYD>)O\ @JY\2KB\E_X0 MWX7^!](T\2'R%\3WNO>(;TQ#A3*VDWNC1)(>I"A@,XR<9/U-'A+#I+V^*J2= MO^7:C!7_ .WE,_6L'X-Y7""^OYOBJU2VOU>-*C&_E[2%=M? 5*$;IN>ON:6ZGW-HFOZ5XAL MQ>Z5=+/$I"RH1LGMY",^7<0M\T3X]>#U4D$X[.+2?"VFS$B/4?$^J;H-+@D Y:VA*RWDX7!\BQFP0V*[L MMP4L=BZ6&C[L6[S?:$=W^B\VCZ+A7(:G$>=X3+(MPI2;G7FMX4*>LVO-Z0CT MYI1/Y<_%7BKQ#XW\1:OXL\6:M=ZYXBUV]EO]5U2]D+SW-Q*>PX6&"- L<4,8 M6.*.-(XU5$ 'ZK0H4L+2A1HP4*=-627]:ONV?UY@<#A[;>LI-MMMMMMG/CDA5!9CT5068X]%&36MTNMCJ;4=VHV[Z'ZT?\$S MR/\ A#OVDL'II_@T?3$7B<5^ _2/_P"37\6VZ9/F'_I$#\E\0_\ DH."O+$5 MO_2J!]V^&_$-[X9U2#4;-F*J52[MLXCN[4L/,A<=-V,E&ZJP!'<'_)KPZX^S M?PZXEP>>Y75E*A&4:>.PG,U2QF$*4K-TJEO>I5$O=FGO;I);2C==K?9%G=P7UI;7MJ^^WNX(KB!QQNCE0. MA([':1D=CQ7^M>4YG@\ZRO+\WRZJJV!S/#T<50FOM4J].-2#:Z/EDE);Q=T] M4?S[B*%3"5ZV&K1Y:M"19KT#$^8/A!^UE\-OC3\1O%WPP\* M:;XMM/$'@NWU>YU6?6]-TZTTN6/1=W+RMMZKF5TTK:(^KSK@_-6&Q[@J2I3 ME*?[RFZL>:,J<4O=3O:3L['T_7FGR@4 % !0!Y/XP^*J>%_%MAX)T[P/XT\: MZ_>^'+GQ4UOX5C\,K#9:/:ZG!I#S7<_B/Q+I*^8U[<1*L;E\33DDE&,NB/7P642Q>#J8ZICL-@<-3K1P_-7=:\JC@ZB45 M1HU791BVV[+H>"=6T'PU>^+H]"\0Z9HYO/$&@:7/ M:6NIWGAR_P!&UZ_TO4I;*XO[%;BU.H17$(O(7>(1R*YTC@:DW#V56G5C*2A> M,G:,FFTI*45))I.SLT[;W.J'#F)KRP_U+&83'4J]:.'=2C4JV^04 % !0 4 % !0 4 % %:]N[? M3[.[OKI_+M;&VGN[APK.4M[:)YIG"("S;8T8X4$G& ,TTM4EZ(J$)3G"G!7E M)J,5YMV7XG.:;XOL=9'A"YT>QU?4M'\9Z%+XATW7[>Q9=(L]/%II=]8+JTL[ MQS6%UJ%MJB-:Q-"S/]DN0_EF+#6Z;C[2[472DHN-];ZIV751MKVNCIJ8.=#Z MW&K.G2K8.JJ4Z3E^\E+FG&7LTDU*--PM-WTYHVO?3K*S.0* .6L?%VF7WC#Q M!X)ABO%U;PSH?AK7[^62*-;%[/Q3=>(;33DMI5F+R7"2>&;\RJT2!1)"59R[ M!-'2E&E3JZG_;RM\SJG@ZM+!X?'-Q]CB:M:E!)^]S4(TI3NK6 M2M6ARN[OKHK:]369RA0 4 % !0 4 % !0 4 % !0 4 % !T]@/PQB@-O*Q\* M?M<_M;7_ ,#);#P9X.T6.\\::QIT>K)K.K+'+H6CZ:\\D"LEI#<";4=2=X7 MBD\B*-2LA:7(CK.V.$_9;_;M>&XC:V%O' M!#+=OI6K6-[>/($CAB80WD,LKN=J2Q9/FE1F[\K6^UOU/-X*\1L1GF/_ +*S M/"QCB*[E*A5H+E@DDY>SJ0E)O1)\LTVWLXOXC])001P01[LP>'/#OAS2' ,5QJNJ303N\K(T; M^5'$,+<0 .7F"#.4VI\K+L?A?XR^,&MZWK>A?%3X7:?X(%AI]G?Z3K MV@^)E\2Z'K;3W$L%Q91R?8X)+.\MPD?"ML8))T_LZ:YVX\[]P$+[P M5EN((]A$F]9YK34.5ZJ]^FG0\6><.&>TLD^H8B2J8=U_K2C^XC9R7(W;?W;- MWTE*,;>]<[BP\6:3J'BGQ#X/M3<-J_A?3O#^IZINB46J6_B5M6734BF$A+SX MT:[9T9%VJT1!;?\ *[ZV['?2QM"KC,5@(-^WP<*-2HK+E4:_M/9V=[W_ '4K MJRLK;W.EIG6% !0 4 % !0 AR =N,@';G@9'3..V:-OD&WR/AOP]^U+\7?%] MSXWC\(?L[R^)[7X?>)M4\+:_/IOQ#TJ&=]1TF:2.=--L;_289[UGBC$D:QH2 M?,5?O9%9*O_ .Q]7\,:OJ^] M8I9&AL[I+Z!652,>274N#Y&_@GX?C9Q8:EKOC76+E06"-=:'I_AZRLMR@X++%X MAOL9&1SCO7V'"--.KC:GVJ<:<5Z3$L7GV*?\2A2PM*/^&K M.O*7XT8GXNZ;8R:EJ.GZ9$ZQ2ZA?6=A%(X)2.2\N8K9'<#G:K2@G'85]M4G[ M*G.=M()NWHKG[S7JJA1JUFKJC"4VEO:$6[?@?T>^'OAWX(_9UTS3O ?PZ\+Z M#:7=EIEB^O\ BV_TJSU'Q'XDU*6%6GN[Z_NXG<1NZEU@'[J+?LA2-$ /^AB*^)JTHXBXRO7A5K5(X?"TZLZ5##TX.R48P:O+6U[IM*\G)MV M]+T"31[WPK\0M:B\-:#H^O7>FVMIK.MZ/I=IIDNO1P+6<1<-X>CC*]?!RKN=+#UJDJGU=J4?:.G?:G M-)/9:P=V[7/(NGMC\,8K^#=O*Q^DGU?\+YY)_!FF>8<^1)>VZ>T<5W,$'_ 0 M-*4 M*/$.,Y%R^TC1F_\ %*E"_P![5SCY/VBOA/#\8(_@1)K]POQ+DV[-$.CZJ+<[ M]&.OJ!JWV3[%DZ6IEQYW7Y/O<5_0"R[%?4_KRIKZLOM^^FQR+A MG.'DCXA6&7]E1WJ^TIWTJ>Q_A\W/\>GP^>Q^*G[/_BK5/!OQ>_:U\0Z%XS\+ M> -5M?#/CF*P\9>+Q;34YT9UXN4;TX?%*U)NUVU9?S.ZLKZG[MQ-A*6-R3@G#5\#7S M&E*MAG+#8>RJU5# 5)*-Y2@H0NDZDG*/+!2LT[,PK[]HOXL_#G5/AYXP\(_M M%?$WXGW-[JMT?%R^(-'\26'PSO)K>_MO*T313XF$9UM)=.FD^T%+"S:U+QM; MLI*E+CEV$Q%/%TJV7TL)[*-X*$HNLM&W)\J]W5::N_7L]Z?#&39G0S7!XWAG M Y.J%*+P_L:M&>.BN25ZE3V":I6G'W/WDU/536Z?T)^VEXI^+WPJ^(-S+X5_ M:>\:SZ[X\U>#4?#'P9\)IJHN/#.B7XBAMH[J[M]6=+<2W(,=I;1V7FW3NQ2- M45GKAR2EA<70_?992C1P\;3Q$^7WI)=$XZ]Y/FT/G. L'DV<9=&.-X3PL<+E MU-PKYGB/9VK5(7;Y8RIIRLM:DG4Y8+1MO0]=USP9^T)X3_9:\.>*/BW^TYXB M^$GB?1=;USQ7XFU2XN=3U[7[C2=;L-/MO#G@1A:ZI:/?:W#<6LTJ64+RJLVH M/&"/*DD'%&M@:F:3I8++88NE)1A"-HQC=-\U3X6E'5:V6BN>'0QW#F,XNQ.$ MR3A2AG.$KTZ>'H4E&G2I*I2E-U<4KTYJ-)J23FTFXP3ZI'.?L 7/[37Q)\8W M'Q+\;?$;QQK/P?TFVUG2["#Q;JE[)#XNU:X0VUM+IVG/-)&T6G\RS7/F2QI/ MB")Y'61HM>(%EN&IPPN'P].GBVXRFX1C[BWLY))W?;335]#K\2(\*97@Z>4Y M=EF%P^=5)4ZE1X>G!?5X+5QG-13O/:,;)N/O223BG]K^,=2\6Z7^TCI$O@_P MKI_BN]D^"&JQW5GJ'B9?"\=K:CQYI+++2C M3>73]K4=-+$QLU'GU]E+2W-&WJ?!X*E@ZO"]:.,Q4\)3CFE-QE"C[=N7U2K[ MKC[2GRJVM[OM;J>>?'OPY\2/%?@SQEX[\:Z/X:\&6?@?X:>.M-\+Z)I6O7/B MZ_O];\6Q:1:W.L:S?G1]*M[?3+2RT[RXK"%)GFDNI))94$,2MO@*E"E6I4:4 MI5/;5:;FW%02C3YFE%7D[MO?HM#T>',3EN"QV"R_ UJV-ECL;A9UZE2E'#QC M2P[J2C3IQ]I5DYSE.[J-I12247=GI7C+PS??#=_ /BO3O&GC74O$5[\2O!'A MSQ)M<68TVSM#9R6\0CEG=OFZGE83%4\Q6882I@<-2PU/! MXFK1C3HPC5HSH4W4IN-=1]M.3Y5&I[2<_:)NZO9KQ7Q5XELK+P!XK\8:%XP^ M-7CWXC:/I^O>(K;X@>$K7QO8_#&'5-'>XO5L+"TO)X/!\G@FV%NMM+ !?"XM MH97\^XNI/,;LHTVZU*E.E0H4).,'3GR.K9Z7>]3G=[IZ6=M$D>Y@L+.IF&#P M6(P>69?EM:=*C+"5Y8:6-<*B4>>4HJ6,6)E?FC+W.2;2Y805E[1X3L_$OC;X MR?$2ZU;QKXEM/"G@^X^&>HZ)X1T75KO3+"76M0\&Z?JVH-JDL#B6[T(LT1&D MATMIY;FZDO$G/E"+DJ^RHX6@H4HNK4]JI3DDWRQJ.,>5;*7>6ZLDFM3Q,9+" M8')LNA1P-&6,Q:QL*N(JPC.2IT\3.G#V::M&K9.]6SG%1A&FXKFOY+9Z=XI@ M_9F7XS-\1_'MQ\2]+\,7'BK2M7NO$NJ3:+;MIU]>%/M2Z5K&DRV<<= MO=F^MI[FY)>;STD$7D]3=/\ M#ZG["G&A*2@XJ*3UBKR4[JLTEM;<]FI M/"OBC^PUEF$CEE6M'#SIQHP51\\(J56-?E=6G4C)N5/V_K/B;0K MSX8:Q\+]>T?QIXMN[[Q%XP_X1;Q=+XL\4:IK&@ZY9:IX3\3ZHVIW^C7MW]@T M6:PU32;.ZA?28M.2&&.:V %O(57FI2C7CB:GF='-<-6P.'A3PF&]OAUAZ$*=6E*G7H4U"-2,?:5%4A.4)*J MZCE)QG\:N>*>(?%=GHG@-/&?A3Q3\;?&_CS3I-!U>?XCPVOCJQ^&6M3R:WIL M.KJNG:S);>%CX(FBGNXX;2QM[C;;O&]K++.JSMU4J3E6]E4IT*5%J25*]-U4 ME%N.L;SYU97;:U6MEH>WA<).OC_J.*PN68'+YJK36#34U&+<3WO0M%F^+?B;XDZGXD\1>+;+1O"GC.^\!>%?#WAGQ3KG MA.ST]-!TW2Y-1\07LOAR^LY]4UN[U:_NVC>ZEFBMK:WMHX8E=IWFXI36%IT( MTX0O')\+EE+"X:A.MBL-'%5ZM>A2 MKRDZLYJ%**K1FH4H4XQ4E%1E.;DY-KE2\SU+6=>M/'#?"WQSKOQ8\7Z!X!\+ MZ=J<]Y\.= \31ZSXMN_%&N^)4\/_ /";ZWX,"7,7]E>%]&L8'2VFLH]3OKF[ MNYH]L$<0ZH4X.A]9I1H49UIN*56<.6"A&/-[.-33WI2;UORQ22W/6HX?#SR] M9M@*&7X+$X^O.G&.,K4/9X>-"E1]K]5I8F\7[6O4E).2FZ%*,*<7[SD.\*>* MO&5M\1_!?A>*3XFV?@)OB#*OAZX^(5CKFE:WJNEWOPN\;ZCJGAC4+C6U2\\2 M:;I&OZ19W=M">68_%26!GCXX1.K'!SI5*5*I'&X:$*T(TKPHSK4JDH3C"T7R MRDE'F:/1?B@U[J_C[5?",VLZ]9:!=_ +QSK,]CH^M:CHV=4T[Q/X9CM;Y)]- MN(98KE;>6XMRZN"T%U-"V8Y64\E"T*4*JC&4XUHQ7-%25G%Z6>CUU]3R)]<^$/PO^!=[X M7UG7;@77P"\8>(?L&NZYJNMZ=/XC?PY\*;/P])=Q:C=R[='TR_U>62&S1HX; M>*:X2%8Q*U=T*<,75Q*J0C%QQ%.*<8J%HWK.5N5;R45=VOHNQ]!#"4,YS//( M8JA2@XYKAJ*E2I0I25'VN/E64>2*_>58TTI3:.)O%VG:CI=UKVK>)/$>LZYH_B^R%U#_PD&GZIX4FOAI6G175BUXMFVEVM MD=.F:W:#,43Q3<#Q,9<\9T*:I--1C",8R@[>ZU.W,[.W-S-\VM^Y\Q/.*5=U MZ5?+<+'!SA.-*G1HTZ53#RY7[*=.NHNK)PERNI[6<_;1YE+WFI+Y^\6:[I+^ M'/B!K]EXO^-'CSQ[IX\;:AIGBKX$IM-T MN&UL[.^:[EU!;R6UNVNI&>4PQ]U*G)5*%/V5"A1E[-.%7V;J23LG)_\ +R\F MVXI6M=6VN?0X/#UEB&+NSTGQ%>>'[KQ#\ M1;[QI:^$KV_DCM]/UZ?1GU".SDDEA*NX$4L4WER)*5&E"A&K90C6Q<8\R;BI M*-)0YTM7%2M??S35R*<,!A*&7TL6H1PU#,,\ITG6C*I1C6C1P<<-*O&-Y2I1 MJ*#J))W2]Z,HWB_2_A1J7A?_ (3:ZTWPQXL^(.ELWAR>?6OA5\5(_&+Z['=0 MWUBMIXJT"X\<3272VL:2W=K?+IMS>V4KWUE(QAD0&XY\1&I[)2J4ZZV\O-J>*^HQJXK"82JHUE&ECL#]75+EY9TC"I%1FES)OE^EZX#Y@* "@ H * "@ H * "@ H * "@#\Z/\ @H/X MR^+GAGPEH5AX,;5M,\ ZU%>VOC?7='LRLL4S211V&E7FMP7AGTVPNHFF#H+6 M!9BHC-TXD:"LJK:LOACU>WHK]/ZU/RGQ1S#/L%@,/3RWVE++JZE'%5:4-4[I M0IRJ*3E",E>ZY(J6W/*[@OQ_T.72]=\4Z/\ \)WX@UFTT.ZO;&UU[7X(I-?U M>QTJ$);F2VM[JY#71@MHTC1#(?+1!L1_+$3Y*RVVZO=_TOP/P+#2HXO'X?\ MM?%UJ>&E*$:U9)U:L*:25XQDTY19.^,B)=H>1NVNONK9 M[?U;N=>34+/1?$4K1S6UII^MW=['):R7;2 M3RRV<2WP)_>&&#S&G-4FT[+6"^=GZ_IK\C]6\*LRX@KXBOA*SJU\FIQG)SJ1 M)_@I\7_!EW\./BY8>&M6O8$TZ[F_LC7K:VTZ:>6]T.]AG>:QN!;! MKJ%HKFXC9(9'BN \)C4C-M\DERR7W?U_70RRGBS$XW$8SA_/,!+*L\HT*DHJ M$G[.M%4Y26U_XE\06!M-5F6Z5]2T\1PVJFWE8KMMU4 M8 YS;DJ4+2=^9*__ &];7N?&/,LTJ>'^3XZ&8XB&85/\ X!V/A+XI_#[XN_$"_P#$>I>,-*\)^*;+QKKL MWB+PQK3^)TN8(M03PU*L=EIBVMZFZ.UM(XHHXV18@AAS(YITDI1DWJDTW=:Z M;=+-]#V>)\%F?#<,#G&5YWC)XJKB88?$0Q55UL/5=92M/V#M3ARRB[1@E&*: MY;-:V_CAX1\4_L]I\/?BOX3^*WQ-UW4F^(?ACPYXWTKQ=XJNM:T+Q7IVOS21 MW;_V*ZI9Z4X>!TCBM(8XXDN%,01H%9B2=/E:E)^]%--WW=MNF_0OB'!8WAG^ MS,ZP.[9QN_4?$>N:_!^V M=X"\,6_B#78/#FJ?"#Q%JU[H$>K7HT275K6]OK2WU/\ LEI6M!?1P!5$ODD_ M(I.2,F[M58J^G*].FC21[&*Q&)AQWEN$CB:T<+6RZM4E152?LO:1=6*G[._) MSI):\O1'B_P:^&=QXB^/?[2'V[XH_%FVF\$>-/ QCO+'Q**UCCMIY8D4!\B8Q]Z?O-._#/@JQ\8ZSX3\">!_ /B6[\(PV5CHGD ZSKU_I@6YU;5K@W,;!)9 M/*C*/A"C(J$4ZEWS.,4VDD[;:7=M;G?DU/$\9?7\SQV98O"8"EB:F'PF$P=> M6'48TU%^UK2A[U2H^963=HR3=N5Q2Q=*\8>/_ FL?M%_L^^)?&?B#Q5%X4^$ M>N_$;X;>.;R_E@\86&FQZ.9HK'4=9M#'-=7EI?7%MY5R2')LI91J58VE*4)R MC:5[WA+[,E&.#H'P\\<>*?V7-(^,TWQJ^*L'Q)TOP'>>+M$N;;Q;?6^@6\.B MK>7T.F7^BJ?+U:2ZM;5A//\ ,(YK0PL\31E'$2C12I<\HTYTEI4YXQ]^.=(3PWXCNO#_@S24T6WNKVUT>'PIIX6UFA MN+*P"W,\YEEDGN9'WB)5A DY04^>49-75G9+Y;&WU',.%J M8NG["M*AAH>P4Y1I+#PM%QG&G:('\ M'^*/CAX=DUKQMXWTZWMQJFGZ/X?LI6U;_A'DD5H;+5=2EL;QUE"'R#L6,*&) M5\TI1I)/EYU=OJDET\RJG$&:9GAN$,IP^*>!QN?T74Q6+A&//"G0C+VGL4]( MSJNG-II>X[)639<^-GA/Q5^S!X=L/C-\./B1\1]=LO#^N:-;^.O!WC_Q9?>+ M]'\3:'JM]#I\UQ&-2RVF:JMQ/"HFMM@ GWH$\K;*24J:YHR?N[INZMUWV^1? M$&#QG"&%I9]E6:XVO3PM6E'%X;&8B>)IUZ522A=<_P %3FE%]I14E^#/S_P#V6K_Q3I\7[3TO@[P_9>(M=?X^^*XK2SU/6$T/3878R[+J M_O?LUQ*;:-]I:.W@DD89"[<[AE&Z]I9:J3MTZ'YEP94QE)<7/ X:.*Q#SG$* M,9U52@M9>].5I-QCUC&+D]E;<\N^,WP-U+X.?L[W"ZEKUGJGC[X@?'KP?XJ\ M1ZOI]J\>BV6LWU[?_8[72K.Y&^73[.6:23=,JM*TKY15VJN['*N1<+S4\3&IF69YMA\16JPC:G"I)U.6-.,DFX0;;O))MR>B5DO4/ MCOX1\4? *W\!_%KPG\5_B=K&L_\ "P?"WA_QAI?BOQ7=:SX?\4Z=KMP\5X&T M)T2RTO#Q,L<5I#''$D_[I4>%&JIITU&2E*_-%.[TU=MNF_0]?B/!8SAN.69U M@LYQ]:NL71HXFGB,0ZE'$0J7*/A/>:QI/@ M[Q?\3?B#I6M6,$FH0^ ?A)>>(5\4:G-=($MKW5H_"%A;E;EG46 M'A.HDE\$9RA#WN9\VEO(_@7X\\8:_P#!O]IC1-8UWQO,WPVO/&=AX/U3Q9=3 M6?Q$TG3H?#=WJ>E6VN:A;2+.NL65Q;H^YG,B,YC8[4"+--OEFKM\K:5][6OK M;JKGA*AAJF)E*&-IPC0G.FJLTU+VD'!.[=TVULDC M0^ 7@SQ/K'P2TKXS>+?BM\2M?\3:G\,/%45II\3:SX7N]/\ &&HV6DZGO);)_M-W>R2R!+ MA(H=D5NJ.H1)G" MG#V,ZCC&<%K5]HX?O)SDY)2Y8VC&SVO!?@[QS\=/V?;?XS>)/B[\1M)^(5WX M(>&%GN+SO&TB^$OC+H?B7]ECP'XG^+GQ(N_ =[XSTQM$O_$.BS_8_ M%.L7>FZE=:;>IX=CL;.YN4U6]M[(&26PM))8OM3O$(G*.CC-.E%RER\RM?K? MR\SUL%GN'Q7"&78O.LUEET\;!TIUJ3Y<15E3J2A)45",Y^TJ1A[SIP M5M->:?!GQI/H?[2FA>!/!FO?&'4/ACXP\!:WJYLOC"VN2RR:QI$TLB:QX2;Q M/''JD6F&. 02-,B+))+, K!$*3!VFHIRY>5Z2O>Z:VOKUU^5CR,BS"6&XLP^ M78#$9G4RC'82I5YYN_A?X@.KW\42;Y%\-ZU;KIFL7"@#=MM[I-)N),<+ M#;RNW$>1]'PQBHX?'NE-\L<3'E6MESQUC^',EYV74_4?"?-J>7\05,#6DH4\ MUH^R@V[+VU)N=-/I[T74C'O)I+<_!?PG_P C5X7_ .QCT+_TZVE?H&(TP];I M:$OR9_1F8:8#&]+4*O\ Z1(_J$\=Z[8:=XHU*RU'P[I^N020Z?<1M<2RVUS; MR?9%C98KB%681$("5P.>6\98+$T,MQ5.>)K5< M)B\-4^ITZ3C1Q5&,YJC)0BY4THWEJV]C^=^&,LQ6+R7!XC!YM7RRI3E7IR5. M,:E.B@E03DJ,?A7&'BSF'$>24N$\ER3 <&<(4:BK/+,MC+_:*L9NU^[C:SC2@KJ": MNMVTFTK)N_(@$D!06)("J!DDDX '4D\8K\IA"W[%E M>>3P%&6%JT(XG#-MJ+=FKZM:IIIO6S7<^KX3X_K<.8&IE.+R^&:9;*4I1IRD MH2ASN\X^]"<9PE+WN645:3;N[V7G?AK_ ()F^!M'^&'CCPAJOCO5]5\9^,_[ M'=?&B:5#;6^@MHE^-3MK:RT1KV5KRUN+O/VMI[S?,JQ&,P-$"W15XEQ$L50K M0HQA1H:T/3Q?BMF-?-\OQU'+Z=# X#VB6%YVW552/( MW*IRKEE&/\/EA:+O?F3LLO4_^""XEOI);6 R7MS-S'%9?PS2H/-%?$3EB9NM4J:KFE-TY144 MI2M3C"*NW*_0O>-O^"<^J>*_BEXB^*UE\?=>\.^(-:UZZUVSGL/"[M?Z(\X, M<%O8:LOBJ*=%MK?$$3H(BD:*JA0HI4.(E0PM/"/ 0J4H146G+25NZY+:O5^9 M&7^)U/!9/ALFGP[0Q.%H4HTI*=?W*J6K+_ /@GMXF\ M=^"O#_A#Q;^TCXP\1OH'B;Q#XB35-?T2[UF2<:UIF@:=;V7V>_\ %TGDK8_V M/>21R>8W_(8N JIEC)%#/XX;$U,11R^G34H1AR1:BERN3;NH?:O9Z+9&>!\2 MRI5(TE'V4ZLW/FAAU?G]HE) +NQOK#P[<6L^EW6GVMNMK_P )5R5I8N.*]IS:IQHRI%FIJ'-R\UKJW-9V^YE?XB> [?XA:/I>B MW5_)86VG^*O#/B.9HH1,]U%X>U6#49-/!\Z/[/\ :DA:'SP6,6_>$8K@JC5= M&3DE=N+BOFK7^0\OQ\LOK5:T*:G*=&K12;LHNI!Q4MG?EWY=+[71X_<_!/XA MZE\-YO@U??$K2+/P#!X6/A"QU+1?"$UIXVNM"M].;3=+L-5OI_$$NFQK%;+: M17X,D?7'%T(5XXJ.'DZRESN,IWIJ5[MJT5+>[2;:BVM[6 M/:AGF6TRAFU"\E\BY M^R"<))*QCW[-SXW'FK5E45.$8\L:7/:[N[2FY:Z+:]CR;5:M*M[S48*\>;ENEK:]EL82?!Z-/@=)\%_[?D,;^%[GPU_PD/]G( M) MP\K_;/[-^V;=R^9CR_M&#C[PS6CQ3^N+%\FJDI?EOK;?E^1N_$OX:67Q+TK0M%U'49["PTG6GU.\6V MA5Y[^UG\->(?#5S8Q2M*OV*1H-?DE6X"S;&MU'EL&.(P^(>'E.<8IN4>57Z> M]&2?G9QM8Y\KS2IE=7$5J5)3G6I9V4)*M2K1DU;WDG22<=+IO56/+=:^# M/Q-\4^ ?^%9:[\3=!M/#5AIFFZ=I]_X?\%3V6O:N-"-G+H8\2/=^)+BT2R6X MT^T:]MM+@LVNT$D<<]K'(5/1#%X>E6^L0P\G4;;:E/W8\UU+EM%.]F^5R;Y> MS/5H9WE>#S#^U,/E=66*G.']9US7? ?C+POILGC0V&H^,-%\0>$]1U70HO%L&F6>DWWBOPM'8^ M);&ZTV2\M+"R$^FW=S>PR/:),)8Y9)VGS]O0G"$*U*+3 MLV[2232=K/2W+_:66XBA0P^/P5>HL#SPPU6E7A3J_5W.52&'KN=&<)J$I2Y: MD(PE%2<>645%1R]/^"NO^#[C3_$G@3QPH\+M)U?\ L25O M!>CK::%J/AK_ (1.Q\'R:R9(_#L^C:OJ:W$XU);^:ZNA>-< PQ0(HXJE"].- M"V'E#DE'F]^7O*2FYVMS*25ER\J2M;5LF&-8=8U+5/A_K M'P^;1="T(Z)H&D:;JNJ6&I&YTE+O5+^Y:]#VDJS37&O&OB>#Q#IG@WP%XQ^&JQZ9H4F M@2:IX9\3:3X7T:REGE;6KYK36;&U\,QRFYAPDD]T'2* 0*'T^NES6E!S?\J]U\]K/9+=W.F7$/L:^-Q&!PKPU3%XK#8R]2JJO)6H3KU)) M+V<%*G-UVN66JC&SE+F=M5?AM\2]8AT7PYXW^(^E:SX,T/4=(U"X.D^%[K1? M%_C :!>V^HZ39^*-7.OW%G;6_P!NL[*6];2["U:^\AD_T:*>2-I]OAX6G@F\^$=I\1-*T_P"&LFFZMH5I M>V'A25/B'#X=U3[8AT8ZQ-K;Z2)X;:\-O_:B:1Y\B1;O+CGLES=+\O-9=[:&\L[R^6.IYQ/+JE3,XSIU90E77U-UJ?+^\ M]FJ:K6;CS>R=;EBW;F<5RN:S^!6NP6TEY_PL*;3/%<7AGX7:)IFLZ!HLEC86 M=]\*[WQ7-IUW>Z1<:SX5'2&1HIHY'B>U'BX74?8*5)2 MJR<92N[55"]I)+E<7"\9)775/6\SS[#N2A_9RJX/V^.JSI5:G-*4<=&@IQC4 MC3C[.I2E04Z-:,6TVE*,DI*6R?AM\0->\0Z7XL\8>-]#AUGPQI^K:=X4A\&^ M&+G3+&P?7I+!-9U746US6M4GU&\GL=/@MHK=6@MX5:5BLTCH\$K$4*4)4Z5& M3A-IS]I--OEORI].3LO=2:E[O7$> % !0 4 % !0 4 % !0 4 % !0!3O\ M3['5+&[TS4[.UU#3KZWEM;VPO8(KFTN[:9#'-;W-O,K)-"Z$JR.I!!Y%%NG0 MBI2IUJ/_@[X>T(_ M8-+M=+UGP3H.EVVC:E>+:$QV^K6)BD2VU.>.V\FW:V\NWE6*W0HTQ^5/^ <1CYT\RR'"T5*C3C3J86E3C2G-1T52+349M1M%QM&2C%6 MYMEP'[*7[&'CVS\>VGC?XL^'=,T70?"M]<+;>&/$-I::U=>(=1B1XH;J*UAN M6MK;3[:2M/YKQ+Y<+(?-51A*ZNK*/1_UT/+X&\/,RP^90S+/,+3H4,) M*2CAZT8U95II64E%2<(PB[2C-\UVERQ:]Y?K?HNA:+X;T^/2?#^DZ;H>F023 M2Q:=I-E;Z?9127$KSW$B6UK&D:O)-([L0N69B3R:V24=$K)'[GA\-A\)25#" MT(8>C%MJ%.,813;NVHQ25VW=Z;G@GC1?VG="\::MJ'PYA^&_C/P)J<5A+9>' M_%^HZGH6N>'[^.TBM]0CM-3T^QDBNM.FN(3H(ESJNI2PWE['O**B"]F(+9C6 C"2ESS:O:R2V2]>OW''EG#N/K9Q/B'B" MK0ECE0>'H8?#*7L^$'@S MQ%\-6^&6HZGKLNA>--536G\9>%]'UZ>>XNK:UT2"-;.[U)#/*8FFF:))I7DW M%-L2S&-2"Y$URWT>MTO3;\3S,OR#BS*,/BSE[.,-$XR3W>R=^VYE'A#- MX<*9=D*GAGB<%C?K$JGM)JG*G&52:2_=-J3E4Y6K62C>^ME[Y^TK\+_%_P 7 M/ WAWPWX4.A6NH:?XV\->*[U];O[RVM4@\/M/<-:026>G7#S333RI&&9(U50 MS\G"U52+E%1C96:>OD[_ *'TG%648W.LOPN%P?LHU*.*HXB7M9RC&U)3]U., M)-MN25[+17\@_:6^%WB_XN^ ]!\,^%3H=IJ-CXU\->*;Q];O[NVM$M] >>Y> MT@DL].N'FFFGDCC#%(U50SGG"DJ1'6C>:I+>WDEU:P+IGV>6W@GE@A >>-G4R/A=JJSY7[12TLHM6Z[I_H* MME&/J\58#.TJ,<)A<)+#SC[27M>:?M)-Q7L^5J+E%*\DVKNRT1B:%\*OBEX" M^/\ XX\;>$+CP?J7PX^+5UH6H^,+;7)]2MO$/AZ^T2R>TDET:&TMVAU'SP\^ MQ99HE4W8W@"W!F2C*,VU;EE:]]U96TW\NQS8;)LWRWB;,,QP,\-5RO.72GB8 MU7-5J,Z46KTE%)_A[XVUNY M\2-X*\%Q:G&,G+DYDDI)M'4+O^PYKF_L]0T^UOFNWTX7 M$< BNXYG06S,"C(N>&HC%PIJ&EXJWEM8,'E&-PO";R.7LGC(X.MA5)3E[*]2 M,X1FYX&GWD BW$0NT9:>/;(DQ(E4VH4U>TZ:T?3:WK9GBO@_&O* M^#?AQINKZ?K'B32/ 6H:WK>L^-Y])F6XM-.DO-6L[6/0]%:Y19'5!/ M-PO)**5;C.5E*T8K=)MMVZ;*WGN;XO)^(^(EA\'GSP6!RJE4A4KTL)*K5J8J M5-WC#FJ**I4N;7[4[V>Z5OLB.*.VAC@MXDCB@B6*"% $1(XD"1Q( ,(BJJJ! MC@"M3[N,5"*C%*,8I)):))*R2[);'S!^S?\ "3QW\*M1^+4WB]O#89+5SJ6-]A*&9XN>+A[*5XXP2JJB[F M)) 4JI%RBDK*S3U\G ="\,>%3H=IJ-EXS\->*+U];O[NWM(X- >:Z>T@DL]. MN'FFEG=(PQCC55#.><+14BY125E9Q>OD[_H3Q5D^-SK+<-A,)[*%6GB:->3J MSDHI4HS]U.,)-MN25[+1-G!W'PC^,?@/XW^-/BM\+4\ >(-/^*=GH5]KC"4'4M9J6J[WLE]W]6(HSE658S \,PRBK[*6+I8:M03C.3IMS]HH-R<%)*TES>Z[:VN9_P ( M/A;XO^'W[.MM\*M5.A7?B?3?#WBC1;:>QO[LZ-=RZM/JL]A/+0KY3%=^0*(1<*:AI>*MIL9Y+D^-RWAA9/5]E+%TJ.(I1<9R]E)U'4<& MY."E'XTI6B[6=KC_ (-_##Q?\.OV>;'X6ZK_ &%=^)](T#Q-H]K/8ZA>'1[R M75;G5+FQFEN9].2>UCSJ*)*!;RE?*8KNR!13BX4XQ=KQ5O+0,CR?&Y9PPLGJ M^REBJ5+$TXN,Y>SDZLZLX-R<%*-O:6E[KVNKWL?/-E^RQ\5/#_@/X!7.AZEX M*G^)/P#U;Q+-9Z;JMQJ=SX-\3Z;X@U1M0;?'*M>4*=1SEAJ].M4]IK)0C* M$XK1>[OJI)QB>DZY\+OCKK?Q1^$'QK4_#?3_ !3XB<4TU=VLVMG9=NR M/6Q.3\15\WR3/HO!4L7A(3P^)H.55THT*DIWE3FES3J1C-NSY(\RBE=7;^R: MU/N@H IZAI]CJUA>Z5J=I!?Z;J5I<6%_8W4:S6UY97<+V]S:W$3@K+#+#(Z, MI!!5B#UIQDX2C*+Y91:::W36J:]"Z52I0J4ZM*;IU:,HSA*+M*,HM.,DULTT MFF?A#\?_ -@3QK\+?'VG>,OA/I5_XP^&,GB;2=0;3+!9+[Q)X,A_M2WFFM;N MR7=/JVBP*&\J^@662.)0+I!Y9GF^ZP'$%+$86>'Q)&!S7*ZV7YS5C@\UC0J0C4E:%'$OD:BU+X:=676$K1;^!N_*OU M!^*I'_"97?M9:?\ A^XK_)+Z3W_)V,Q\L!EW_J.CQ>!U;AZAT_?5_P#TL\^@ M@FN94@M89;B9R%2&"-Y97)Z!8XP6/X"OP; X#'9EB:6"RW!U\?BZ[4:='#TI MUJLWT4:=.,I2?HCZNI5IT(.K6J1HTXJ[E.2A%+S,*=>E4RW*9N5.:<: MV(5TG'9TZ5[.TMI3TNM(Z-L]RK^S3\U"@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ M H * "@ H S[O2-*OFWWVF:?>. 'N[*VN& '0;IHF.!7A9IPMPSG=15J XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 04, 2022
Cover [Abstract]  
Entity Registrant Name Jazz Pharmaceuticals plc
Amendment Flag false
Entity Central Index Key 0001232524
Document Type 8-K
Document Period End Date May 04, 2022
Entity Incorporation State Country Code L2
Entity File Number 001-33500
Entity Tax Identification Number 98-1032470
Entity Address, Address Line One Fifth Floor
Entity Address, Address Line Two Waterloo Exchange
Entity Address, Address Line Three Waterloo Road
Entity Address, City or Town Dublin 4
Entity Address, Country IE
Entity Address, Postal Zip Code D04 E5W7
City Area Code 011-353-1
Local Phone Number 634-7800
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Ordinary shares, nominal value $0.0001 per share
Trading Symbol JAZZ
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d197099d8k_htm.xml IDEA: XBRL DOCUMENT 0001232524 2022-05-04 2022-05-04 Jazz Pharmaceuticals plc false 0001232524 8-K 2022-05-04 L2 001-33500 98-1032470 Fifth Floor Waterloo Exchange Waterloo Road Dublin 4 IE D04 E5W7 011-353-1 634-7800 false false false false Ordinary shares, nominal value $0.0001 per share JAZZ NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( """I%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " @@J14P+H/CN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R''7PDR:RT9/'0Q6V-C-V&IK&L?&UDCZ]G.R-F5L#["CI=^? M/H%J':3V$5^B#QC)8KH;7-LEJ<.:'8F"!$CZB$ZE,B>ZW-S[Z!3E9SQ 4/JD M#@B"\Q4X)&44*1B!19B)K*F-ECJB(A\O>*-G?/B,[00S&K!%AQTEJ,H*6#-. M#.>AK>$&&&&$T:7O IJ9.%7_Q$X=8)?DD.R&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" @@J14);KLCF0$ "1$0 & 'AL+W=O_0L/T,HEM\9D=8(9 TK*[2=A FYET>B%L 9JU)5>20]A? MWR-#;'9KCIG>@&UT7C_2D=XCT=\J_Z!-^RG;,WGW/Z1SC3<>85*)!(NC5"2:+X:-$;!QQO: M<0%YBS\%WYJC:^*ZLE3JF[N91H.&[XAXS$/K)!A\O?(QCV.G!!S_'$0;Q3M= MX/'UN_I=WGGHS)(9/E;QLXCL9M#H-4C$5RR+[9/:_LX/'6H[O5#%)O\DVWW; MEM\@86:L2@[!0) (N?]F;X>!. ZX/A% #P$TY]Z_**><,,N&?:VV1+O6H.8N M\J[FT0 GI,O*W&KX54"<'4Y4F,$@6\)D1&ZE%79'IG*?;1BUOF?A):ZI%QX$ M;_:"](3@/=L1OW5!J$_IC]$>H!5\M."CN5SSA-Q8O7)-_AHMC=60P;\1R68A MV61&RV) T#A'$5H'8 M0J5'D)(H3\M=S-95:'C\"E XPM$N.-KG#-482#2+86)$_(U\YKLJ(ES)]_V M-FF;MA"L3H'50<6*2;O8I96)P\-[EY\1B&X!T3T/8L:U4&[Q1 268"4/KN26 M3.OBEP\?:M9,KR#KG9.UJ0R53I7.%S*96V C8Y5!*B&C*JH$Q86_8'37!=WU M.71W(N;D(4N67%>!X!HPF2Z;S;;O(SR!7UJ@?P[1@KV1:009%2M8R_F@G>:K MD;SN709^D[:Z*.&120?G$(ZB2'-C+MXOR!=H1QYE92IK)._$RF[ 7I32&&+I MTP']_XB+K:I$Q"6?8<9J "2W;^&&R37F:$'I_L%9]G\"=*-Y]6CBH@7JDV(1 MAEE6@ "W\)\QQ^Y.:;)0V^JJC,M-LB4\(IC[!F55",XJ"R7;WE4JL7"EZ2T& M5-:# '?TGX%FREBH5R\B/>ET-8H3OT5NV\]=#*^L% %N\'GN1K!I/DV#"_@! M^%V[>1E@.&5Y"&IL7,%6!78N2F(.7"/2:;8NNSW<@,V_1^RJ3$9D-4"XK*U@*7C4]R:!:Y&3C?)4M5/?]P@4^CEQ>,I+1\BAMU,8;OM?CDH:E&Z&$T MGXR^8DREZ].S7/\VX7KM1NDW4( ]#'+*>4<';/=GQ3US;S0D MYBL0\J^ZT&>]/__O;ZQ*\S/W4EDXP>>7&\Y@.;@&\/M**?M^XX[QQ;\PPW\! M4$L#!!0 ( """I%2?H!OPL0( .(, - >&PO9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8Q MYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_* M%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2 M,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T] M.PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D M'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3 M\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_R MBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P M6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8 MLAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z M'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8 M"<:1/,<0F,7XC&894IT,/O'^8* \^ M>Q\ETWLJ.?]74_P$4$L#!!0 ( """I%27BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d197099d8k.htm d197099dex991.htm jazz-20220504.xsd jazz-20220504_lab.xml jazz-20220504_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d197099d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d197099d8k.htm" ] }, "labelLink": { "local": [ "jazz-20220504_lab.xml" ] }, "presentationLink": { "local": [ "jazz-20220504_pre.xml" ] }, "schema": { "local": [ "jazz-20220504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "jazz", "nsuri": "http://www.jazzpharma.com/20220504", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d197099d8k.htm", "contextRef": "duration_2022-05-04_to_2022-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d197099d8k.htm", "contextRef": "duration_2022-05-04_to_2022-05-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.jazzpharma.com//20220504/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-140479-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-140479-xbrl.zip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end